USP General Chapter 800 exists to protect healthcare workers, patients, and the environment from the risks of hazardous drug exposure. Published by the United States Pharmacopeial Convention (USP), it sets enforceable standards for every step in a hazardous drug’s journey through a healthcare facility, from the moment it arrives at a loading dock to the moment contaminated waste leaves the building. The chapter applies broadly, covering not just pharmacists who compound these drugs but nurses who administer them, technicians who unpack shipments, and housekeeping staff who clean the areas where hazardous drugs are handled.
What the Chapter Actually Covers
USP 800 addresses hazardous drug handling related to receipt, storage, compounding, dispensing, administration, and disposal of both sterile and nonsterile products and preparations.1PubMed Central. USP <800>: Key Considerations and Changes for Health Systems That breadth is deliberate. Before USP 800, guidance on hazardous drugs was scattered across multiple standards and recommendations from different organizations. The chapter consolidates those requirements into a single reference that healthcare facilities can follow end to end.
The drugs covered include antineoplastic agents used in cancer treatment, certain hormonal therapies, some antiviral medications, and other compounds that meet established criteria for toxicity. The chapter does not only apply to intravenous chemotherapy mixed in a sterile clean room. It extends to oral tablets of hazardous drugs that a nurse might handle at bedside, topical formulations, and even investigational drugs used in clinical trials. If a drug poses a health risk to the people handling it, USP 800 likely applies.
How It Differs from USP 797
A common point of confusion is how USP 800 relates to USP General Chapter 797, the longstanding standard for sterile compounding. USP 797 covers the compounding of both hazardous and nonhazardous sterile drugs, with the primary goal of preventing microbial contamination and ensuring the sterility of the finished product. USP 800, by contrast, exists specifically to guide the handling of hazardous drugs in order to protect patients, healthcare personnel, and the environment.1PubMed Central. USP <800>: Key Considerations and Changes for Health Systems The two chapters overlap when a pharmacy compounds a hazardous sterile preparation, because both the sterility requirements of 797 and the worker-safety requirements of 800 apply simultaneously. But USP 800 reaches far beyond the compounding area into storage rooms, nursing stations, and waste-disposal workflows that USP 797 never touched.
Why Hazardous Drug Exposure Matters
The urgency behind USP 800 comes from decades of evidence that healthcare workers can absorb hazardous drugs through skin contact, inhalation of aerosols or vapors, and accidental ingestion. The drugs most studied are antineoplastic agents, which are designed to kill rapidly dividing cells in cancer patients. The problem is that those same cell-killing properties do not distinguish between a patient’s tumor cells and a nurse’s healthy cells. Research has documented that healthcare workers with chronic, low-level occupational exposure to antineoplastic drugs appear to have an increased risk of adverse reproductive outcomes, including miscarriage and congenital abnormalities.2PubMed Central. Reproductive Health Risks Associated with Occupational Exposures to Antineoplastic Drugs in Health Care Settings: A Review of the Evidence Other reported health effects in exposed workers include skin rashes, hair loss, and abnormalities in blood cell counts. The doses involved are far smaller than what a patient receives during treatment, but the exposure is repeated over months and years of a healthcare career.
Surface contamination studies have consistently shown that hazardous drug residues can be found on countertops, floors, door handles, and other surfaces well outside the compounding area. Drugs can escape during routine activities like breaking a tablet, priming an IV line, or disconnecting tubing after an infusion. These findings made clear that simply requiring gloves during compounding was not enough. A comprehensive approach covering the entire medication-use process was needed.
Personal Protective Equipment Requirements
USP 800 specifies the types of personal protective equipment (PPE) that must be used at each stage of hazardous drug handling, and the requirements are more specific than many facilities were accustomed to before the chapter took effect. For gloves, the standard calls for chemotherapy-tested gloves that comply with ASTM standard D-6978, and they must be powder-free. Acceptable materials include nitrile, polyurethane, and neoprene. Latex gloves are permitted but carry allergy risks, and vinyl gloves should not be used because they provide inadequate protection against drug permeation.3PubMed Central. Safe handling of hazardous drugs The chapter also recommends adjusting how often gloves are changed based on the level of exposure at each step in the medication process, recognizing that a technician compounding an IV bag faces different conditions than a nurse handing a patient an oral tablet.
Beyond gloves, USP 800 addresses protective gowns, eye and face protection, and respiratory protection. Gowns used during compounding must be disposable, lint-free, and made of a material tested for resistance to hazardous drug permeation. For activities that could generate aerosols or splashes, such as reconstituting a powdered drug or cleaning a spill, additional face shields or goggles and respiratory protection come into play. The chapter lays out which combinations of PPE are appropriate for different tasks, moving away from the old approach where individual facilities made those decisions with varying levels of rigor.
Engineering Controls and Facility Design
PPE is considered a last line of defense. USP 800 places heavy emphasis on engineering controls, meaning the physical infrastructure designed to contain hazardous drug vapors and particulates before they ever reach a worker. The most prominent requirement is the use of containment primary engineering controls (C-PECs), which are specialized ventilated cabinets or isolators designed to capture drug particles and vapors during compounding. For sterile hazardous drug compounding, the C-PEC must be placed within a containment secondary engineering control (C-SEC), essentially a negative-pressure room with dedicated ventilation that prevents contaminated air from drifting into adjacent spaces.
These ventilation and containment requirements represent one of the most significant facility upgrades the chapter demands. Many pharmacies that were built to comply with USP 797’s clean-room standards found that their existing rooms did not meet USP 800’s negative-pressure and air-exchange requirements. The chapter also addresses closed-system drug-transfer devices (CSTDs), which are engineered to mechanically prevent the escape of drug vapor or liquid during the transfer of drugs between vials, syringes, and IV bags. USP 800 requires CSTDs for the administration of antineoplastic drugs and strongly encourages their use during compounding as a supplemental control.
Environmental Wipe Sampling
One of the more distinctive elements of USP 800 is its requirement for routine environmental monitoring through surface wipe sampling. Facilities must collect wipe samples from surfaces in and around hazardous drug handling areas to test for drug residue contamination. The chapter calls for initial sampling to establish baseline contamination levels and then ongoing sampling at least every six months to verify that containment strategies are working.4PubMed Central. Developing wipe sampling strategy guidance for assessing environmental contamination of antineoplastic drugs
The chapter lists several specific surfaces as candidate sampling locations, such as the interior of biological safety cabinets, countertops in drug preparation areas, and floors near waste containers. However, the list is not comprehensive, and the chapter does not specify which drugs or combinations of drugs should be tested for.4PubMed Central. Developing wipe sampling strategy guidance for assessing environmental contamination of antineoplastic drugs This ambiguity has left facilities to develop their own sampling strategies, and researchers have been working on standardized guidance to fill the gap. The value of wipe sampling is that it provides objective data. A facility may believe its containment procedures are effective, but if cyclophosphamide residue keeps showing up on a break-room door handle, something in the workflow is broken.
Who Enforces It
This is a detail that surprises many healthcare professionals. USP itself does not enforce its own standards. The United States Pharmacopeial Convention is a scientific nonprofit organization, not a regulatory agency. However, USP standards are enforceable by federal and state agencies, including the Food and Drug Administration and state boards of pharmacy.5PubMed Central. USP <800>: Handling Hazardous Drugs In practice, state boards of pharmacy are the primary enforcement mechanism, because they license pharmacies and can make compliance with USP chapters a condition of licensure. The timeline and stringency of enforcement have varied widely by state. Some states adopted USP 800 requirements quickly, while others delayed or incorporated only parts of the chapter into their regulations.
The Occupational Safety and Health Administration (OSHA) also plays an indirect role. OSHA does not specifically reference USP 800 in its regulations, but it enforces general duty clause requirements that obligate employers to maintain a workplace free from recognized hazards. A facility that ignores USP 800’s well-known safeguards could face OSHA scrutiny if a worker is harmed by hazardous drug exposure. Accrediting bodies like The Joint Commission and the Accreditation Commission for Health Care also factor USP compliance into their assessments, adding another layer of accountability.
The Cost of Compliance
Implementing USP 800 has been expensive. The chapter requires millions of dollars in capital outlays for facility and equipment upgrades across the healthcare system, along with in-depth assessments of each hazardous drug a facility handles, significant workflow changes, and thorough staff training.6PubMed Central. USP <800> Adds Significant Safety Standards: Facility Upgrades Needed to Protect Employees From Hazardous Drugs For large hospital systems with multiple pharmacy locations, the costs include constructing or renovating negative-pressure rooms, purchasing new ventilated cabinets, upgrading HVAC systems, and stocking chemotherapy-tested PPE in quantities that were not budgeted before. Smaller facilities, including community pharmacies and outpatient clinics that handle oral hazardous drugs, face proportionally smaller but still meaningful costs for equipment, training, and documentation.
The financial burden has been a real source of tension. Critics have argued that some requirements, particularly the engineering controls for nonsterile hazardous drugs like oral tablets, impose costs that are disproportionate to the exposure risk. Proponents counter that the evidence of harm to healthcare workers, accumulated over decades, makes the investment necessary and overdue. Many facilities phased in compliance over several years, prioritizing the highest-risk activities first and tackling lower-risk areas over time.
Compliance Gaps in Practice
Despite the clear standards, real-world compliance has been uneven. A survey of veterinary oncology practices found that while containment primary engineering controls and closed-system transfer devices were used at the vast majority of hospitals surveyed, only about one in five actually met USP 800 standards overall.7PubMed Central. Engineering controls in veterinary oncology: A survey of 148 ACVIM board-certified oncologists and environmental surveillance in 20 specialty hospitals Notably, oncologists at some of those hospitals did not even know the type of containment engineering their own facility used. While this particular data comes from veterinary settings, the pattern of partial compliance and knowledge gaps echoes findings across human healthcare as well.
The gap between what USP 800 requires on paper and what happens in daily practice often comes down to the less visible elements of the chapter. Facilities tend to invest in the obvious hardware, such as ventilated cabinets and CSTDs, but fall short on documentation, training refreshers, environmental monitoring, and the assessment of alternative containment strategies for specific drugs. Staff turnover compounds the problem. A pharmacy may train all employees at the time of implementation, but new hires six months later may receive abbreviated orientation that skips the reasoning behind the requirements.
Beyond the Hospital Pharmacy
USP 800 applies to all healthcare settings where hazardous drugs are handled, and that scope is broader than many people realize. It includes physician offices where oral chemotherapy is dispensed, home health agencies whose nurses administer hazardous drugs in patients’ living rooms, long-term care facilities, and veterinary hospitals. The chapter’s requirements do not change based on setting, although the practical implementation looks different when a nurse is working in a patient’s kitchen versus a purpose-built hospital clean room.
Home healthcare presents unique challenges. A hospital can install a negative-pressure room, but a patient’s home obviously cannot be retrofitted with specialized ventilation. USP 800 still requires appropriate PPE and safe handling procedures in these settings, but the lack of engineering controls places a greater burden on administrative controls and worker education. Caregivers and family members who help patients take oral hazardous drugs at home are generally not covered by USP 800’s requirements, which apply to healthcare personnel rather than lay caregivers. This creates a practical gray area, since the exposure risk does not disappear just because the person handling the drug is not a licensed professional.
How Hazardous Drug Lists Are Determined
USP 800 does not create its own list of hazardous drugs from scratch. It references the National Institute for Occupational Safety and Health (NIOSH) list of antineoplastic and other hazardous drugs used in healthcare settings as a starting point. The NIOSH list categorizes drugs into groups based on the type and degree of hazard they pose. Facilities are then required to maintain their own internal list of hazardous drugs based on the NIOSH list, review it at least annually, and add any new drugs that meet the criteria.
The assessment of risk is not one-size-fits-all. USP 800 uses a concept called an assessment of risk, where each facility evaluates the specific hazardous drugs it handles and the activities performed with those drugs, then tailors its containment strategies accordingly. A pharmacy that compounds large volumes of antineoplastic IV bags faces different requirements than a retail pharmacy that dispenses a bottle of oral methotrexate. The chapter establishes a floor of minimum requirements but expects facilities to go further when their own risk assessment indicates it.
This flexible, risk-based framework is one of the more pragmatic elements of USP 800. It acknowledges that a rural community pharmacy and a major cancer center operate in very different worlds, while insisting that both take concrete, documented steps to protect the people who handle hazardous drugs within their walls.
Training and Documentation Expectations
USP 800 requires that all personnel who handle hazardous drugs receive training before they begin working with those drugs and at least every twelve months thereafter. Training must cover the facility’s specific policies, the proper use of PPE, spill management, and the health risks associated with hazardous drug exposure. Competency assessments are required, meaning facilities cannot simply have employees watch a video and sign a form. Workers must demonstrate that they can correctly don and doff PPE, use containment equipment, and respond to a spill.
Documentation requirements extend well beyond training records. Facilities must maintain records of their hazardous drug list, risk assessments, environmental monitoring results, spill incidents, and medical surveillance activities. For many smaller practices, this documentation burden has been one of the more challenging aspects of compliance, requiring dedicated time and sometimes new record-keeping systems that did not previously exist. The chapter treats documentation as integral to the safety program rather than as bureaucratic overhead, because without records, there is no way to identify trends, track contamination, or demonstrate that safeguards are actually in place.